LGALS3 and cancer: Our results successfully identified the significant association of high galectin-3 expression with reduced DFS/RFS/PFS in overall cancer patients (pooled HR = 1.57, 95% CI 1.04–2.37, I2= 67.1%, p = 0.001; Fig. 3a).